Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1 Terminated 74 enrolled AbbVie

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with relapsed and refractory multiple myeloma.

Timeline

Start: 2015-05-06
Primary completion: 2017-12-06
Completion: 2017-12-06

Publications

Vij R, Nath R, Afar DEH, Mateos MV, Berdeja JG, Raab MS, Guenther A, Martinez-Lopez J, Jakubowiak AJ, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan JP, Reddy A, Paiva B, Singhal A, San-Miguel JF, Moreau P. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2308-2317. doi: 10.1158/1078-0432.CCR-19-1431. Epub 2020 Jan 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZINTUXIZUMAB VEDOTIN	Unknown	0.6 mg/kg	Intravenous
Subject	AZINTUXIZUMAB VEDOTIN	Unknown	5 mg/kg	Intravenous
Subject	AZINTUXIZUMAB VEDOTIN	Unknown	6 mg/kg	Intravenous
Background	Dexamethasone	Small molecule	—	Oral
Background	Pomalidomide	Other / unclassified	—	Oral

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications